Birociclib Application Scope

Birociclib is indicated for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in adult patients who have progressed on or after prior endocrine therapy.

Birociclib Characteristics

Ingredients: 120 mg per tablet
Properties: Selective CDK4/6 inhibitor
Packaging Specification: 120 mg × 36 tablets per bottle
Storage: Store at 2–8°C, protected from light
Expiry Date: 24 months from the date of manufacture
Executive Standard: In line with Chinese Pharmacopoeia standards
Approval Number: National Drug Approval No. H20250001 (China)
Date of Revision: May 2025
Manufacturer: Xuanzhu Pharmaceutical Technology Co., Ltd., China

Guidelines for the Use of Xuanyuening

Dosage and Administration:
- Recommended Dose: 120 mg twice daily
- Administration: Take with or without food
- Missed Dose: Take as soon as remembered; skip if near next dose, do not double
Adverse Reactions:
- Common Adverse Reactions: Neutropenia, fatigue, nausea
- Serious Adverse Reactions: Neutropenia
Contraindications: Hypersensitivity to it or excipients
Precautions: Use with caution in patients with liver dysfunction

Birociclib Interactions

No significant drug interactions reported
Avoid concurrent use with strong CYP3A inhibitors or inducers

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.